249 related articles for article (PubMed ID: 23329849)
21. Human immunodeficiency virus type 1 shedding pattern in semen correlates with the compartmentalization of viral Quasi species between blood and semen.
Gupta P; Leroux C; Patterson BK; Kingsley L; Rinaldo C; Ding M; Chen Y; Kulka K; Buchanan W; McKeon B; Montelaro R
J Infect Dis; 2000 Jul; 182(1):79-87. PubMed ID: 10882584
[TBL] [Abstract][Full Text] [Related]
22. Effect of raltegravir intensification on HIV proviral DNA in the blood and gut mucosa of men on long-term therapy: a randomized controlled trial.
Chege D; Kovacs C; la Porte C; Ostrowski M; Raboud J; Su D; Kandel G; Brunetta J; Kim CJ; Sheth PM; Kaul R; Loutfy MR
AIDS; 2012 Jan; 26(2):167-74. PubMed ID: 22089379
[TBL] [Abstract][Full Text] [Related]
23. Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc.
Armstrong-James D; Stebbing J; Scourfield A; Smit E; Ferns B; Pillay D; Nelson M
Antiviral Res; 2010 May; 86(2):224-6. PubMed ID: 20211653
[TBL] [Abstract][Full Text] [Related]
24. Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study.
Katlama C; Assoumou L; Valantin MA; Soulié C; Duvivier C; Chablais L; Kolta S; Pialoux G; Mercié P; Simon A; Costagliola D; Peytavin G; Marcelin AG;
J Antimicrob Chemother; 2014 Jun; 69(6):1648-52. PubMed ID: 24535278
[TBL] [Abstract][Full Text] [Related]
25. Disproportionately high semen shedding of HIV is associated with compartmentalized cytomegalovirus reactivation.
Sheth PM; Danesh A; Sheung A; Rebbapragada A; Shahabi K; Kovacs C; Halpenny R; Tilley D; Mazzulli T; MacDonald K; Kelvin D; Kaul R
J Infect Dis; 2006 Jan; 193(1):45-8. PubMed ID: 16323130
[TBL] [Abstract][Full Text] [Related]
26. Shedding of HIV and human herpesviruses in the semen of effectively treated HIV-1-infected men who have sex with men.
Gianella S; Smith DM; Vargas MV; Little SJ; Richman DD; Daar ES; Dube MP; Zhang F; Ginocchio CC; Haubrich RH; Morris SR;
Clin Infect Dis; 2013 Aug; 57(3):441-7. PubMed ID: 23595831
[TBL] [Abstract][Full Text] [Related]
27. Molecular biological assessment methods and understanding the course of the HIV infection.
Katzenstein TL
APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
[TBL] [Abstract][Full Text] [Related]
28. Penetration and antiviral efficacy of total and unbound maraviroc, raltegravir and rilpivirine in both female and male genital fluids from HIV-positive patients receiving regimens containing these antiretrovirals.
Lê MP; Belarbi L; Chaix ML; Dulioust E; Mahjoub N; Salmon D; Viard JP; Duvivier C; Peytavin G; Launay O; Ghosn J
J Antimicrob Chemother; 2017 Nov; 72(11):3167-3171. PubMed ID: 28961979
[TBL] [Abstract][Full Text] [Related]
29. Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy.
McMahon D; Jones J; Wiegand A; Gange SJ; Kearney M; Palmer S; McNulty S; Metcalf JA; Acosta E; Rehm C; Coffin JM; Mellors JW; Maldarelli F
Clin Infect Dis; 2010 Mar; 50(6):912-9. PubMed ID: 20156060
[TBL] [Abstract][Full Text] [Related]
30. The effect of intensification with raltegravir on the HIV-1 reservoir of latently infected memory CD4 T cells in suppressed patients.
Vallejo A; Gutierrez C; Hernandez-Novoa B; Diaz L; Madrid N; Abad-Fernandez M; Dronda F; Perez-Elias MJ; Zamora J; Muñoz E; Muñoz-Fernandez MA; Moreno S
AIDS; 2012 Sep; 26(15):1885-94. PubMed ID: 22992577
[TBL] [Abstract][Full Text] [Related]
31. Maraviroc (Celsentri) for multidrug-resistant human immunodeficiency virus (HIV)-1.
Ndegwa S
Issues Emerg Health Technol; 2007 Dec; (110):1-8. PubMed ID: 18080399
[TBL] [Abstract][Full Text] [Related]
32. The CD4/CD8 ratio in HIV-infected subjects is independently associated with T-cell activation despite long-term viral suppression.
Serrano-Villar S; Gutiérrez C; Vallejo A; Hernández-Novoa B; Díaz L; Abad Fernández M; Madrid N; Dronda F; Zamora J; Muñoz-Fernández MÁ; Moreno S
J Infect; 2013 Jan; 66(1):57-66. PubMed ID: 23046968
[TBL] [Abstract][Full Text] [Related]
33. HIV Transmission Risk Persists During the First 6 Months of Antiretroviral Therapy.
Mujugira A; Celum C; Coombs RW; Campbell JD; Ndase P; Ronald A; Were E; Bukusi EA; Mugo N; Kiarie J; Baeten JM;
J Acquir Immune Defic Syndr; 2016 Aug; 72(5):579-84. PubMed ID: 27070123
[TBL] [Abstract][Full Text] [Related]
34. The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS clinical trials group protocol 850).
Eron JJ; Smeaton LM; Fiscus SA; Gulick RM; Currier JS; Lennox JL; D'Aquila RT; Rogers MD; Tung R; Murphy RL
J Infect Dis; 2000 May; 181(5):1622-8. PubMed ID: 10783117
[TBL] [Abstract][Full Text] [Related]
35. Different outcomes in patients achieving complete or partial viral load suppression on antiretroviral therapy.
de Mendoza C; Soriano V; Pérez-Olmeda M; Rodés B; Casas E; González-Lahoz J
J Hum Virol; 1999; 2(6):344-9. PubMed ID: 10774551
[TBL] [Abstract][Full Text] [Related]
36. Early human immunodeficiency virus (HIV) infection in the HIV Network for Prevention Trials Vaccine Preparedness Cohort: risk behaviors, symptoms, and early plasma and genital tract virus load.
Celum CL; Buchbinder SP; Donnell D; Douglas JM; Mayer K; Koblin B; Marmor M; Bozeman S; Grant RM; Flores J; Sheppard HW
J Infect Dis; 2001 Jan; 183(1):23-35. PubMed ID: 11106536
[TBL] [Abstract][Full Text] [Related]
37. Seminal reservoirs during an HIV type 1 eradication trial.
Nunnari G; Leto D; Sullivan J; Xu Y; Mehlman KE; Kulkosky J; Pomerantz RJ
AIDS Res Hum Retroviruses; 2005 Sep; 21(9):768-75. PubMed ID: 16218800
[TBL] [Abstract][Full Text] [Related]
38. Intermittent shedding of human immunodeficiency virus in semen: implications for sexual transmission.
Krieger JN; Coombs RW; Collier AC; Ho DD; Ross SO; Zeh JE; Corey L
J Urol; 1995 Sep; 154(3):1035-40. PubMed ID: 7637049
[TBL] [Abstract][Full Text] [Related]
39. HIV-RNA decay in paired blood and semen samples of subjects receiving their first dolutegravir-based ART regimen.
Fabrizio C; de Gennaro N; Volpe A; Scudeller L; Lagioia A; Falasca K; Ladisa N; Angarano G; Monno L; Saracino A
J Clin Virol; 2018 Dec; 109():45-49. PubMed ID: 30471517
[TBL] [Abstract][Full Text] [Related]
40. CD4 T cell nadir independently predicts the magnitude of the HIV reservoir after prolonged suppressive antiretroviral therapy.
Boulassel MR; Chomont N; Pai NP; Gilmore N; Sékaly RP; Routy JP
J Clin Virol; 2012 Jan; 53(1):29-32. PubMed ID: 22019250
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
